Onkologie. 2014:8(6):264-268

Cardiovascular side effects of antitumour drugs

David Dufek, Tibor Stračina, Marie Nováková
Fyziologický ústav, Lékařská fakulta, Masarykova univerzita, Brno

Cancer represents the second most frequent cause of mortality in the Czech Republic as well as in all other EU member countries. In 2010, there

were 82 606 new cases of malignant tumours reported to National oncology registry of the Czech Republic, which means about 4 % increase as

compared to 2009. Taking into account that cardiovascular diseases are foremost reason of death in European countries and cardiotoxicity of

chemotherapy is well known, there is a need to search for new cardioprotective techniques and improvements of actual anti-tumour protocols.

This review focuses on cardiotoxic effects of main groups of cytostatic drugs and on potential methods decreasing these adverse side effects.

Keywords: antitumor drugs, cardiovascular side effects, cardioprotection

Published: December 15, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dufek D, Stračina T, Nováková M. Cardiovascular side effects of antitumour drugs. Onkologie. 2014;8(6):264-268.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Novotvary 2010. Praha: Ústav zdravotnických informací a statistiky ČR, 2010.
    2. Statistika příčin úmrtí. Eurostat, 2012. dostupné online: http://epp.eurostat.ec.europa.eu/statistics_explained/index.php/Causes_of_death_statistics/cs (25. 7. 2014).
    3. Demografická ročenka České republiky 2012. Praha: Český statistický úřad, 2010.
    4. Drabl?s F, Feyzi E, Aas PA, et al. Alkylation damage in DNA and RNA repair mechanisms and medical significance. DNA Repair 2004; 3: 1389-1407. Go to original source... Go to PubMed...
    5. Dhesi S, Chu MP, Blevins G, et al. Cyclophosphamide-Induced Cardiomyopathy: A Case Report, Review, and Recommendations for Management. Journal of Investigative Medicine High Impact Case Reports 2013: 1-7. Go to original source... Go to PubMed...
    6. Katayama M, Imai Y, Hashimoto H, et al. Fulminant fatal cardiotoxicity following cyclophosphamide therapy. J Cardiol 2009; 1: 330-334. Go to original source... Go to PubMed...
    7. Nováková Z, Šťastná J, Honzíková N, et al. Anthracycline Therapy and 24-Hour Blood-Pressure Profile in Long-Term Survivors of Childhood Cancer. Physiol. Res. 2010; 59: 97-102. Go to original source... Go to PubMed...
    8. Hrstková H, Honzíková N, Fišer B, Závodná E, Novotný J. Vztah mezi anamnesticky zjištěnou aktivitou a baroreflexní senzitivitou po léčbě antracykliny. Čes slov Pediat 2000; 5: 281-287.
    9. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 2010; 7: 564-575. Go to original source... Go to PubMed...
    10. Swain SM, Whaley FS, Ewer MS, Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 2013; 97: 2869-2879. Go to original source... Go to PubMed...
    11. Ritchie DS, Seymour JF, Roberts AW, Szer J, Grigg AP. Case report: Acute left ventricular failure following melphalan and fludarabine conditioning. Bone Marrow Transplantation 2001; 28: 101-103. Go to original source... Go to PubMed...
    12. Sledge GW, Neuberg D, Bernardo P, et al. Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193). Journal of Clinical Oncology, 2003; 4: 588-592. Go to original source... Go to PubMed...
    13. Untch M, Muscholl M, Tjulandin S, et al. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. J Clin Oncol 2010; 28: 1473-1480. Go to original source... Go to PubMed...
    14. Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 2011; 29: 632-638. Go to original source... Go to PubMed...
    15. Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: With a special focus on cardiac repolarisation (QT interval). Drug Saf 2013; 36: 295-316. Go to original source... Go to PubMed...
    16. Todorova V, Vanderpool D, Blossom S, et al. Oral glutamine protects against cyclophosphamide-induced cardiotoxicity in experimental rats through increase of cardiac glutathione. Nutrition 2009; 25: 812-817. Go to original source... Go to PubMed...
    17. Legha SS, Benjamin RS, Mackav B, et al. Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion. Ann Intern Med 1982; 96: 133-139. Go to original source... Go to PubMed...
    18. Blazkova I, Nguyen HV, Dostalova S, et al. Apoferritin Modified Magnetic Particles as Doxorubicin Carriers for Anticancer Drug Delivery. Int J Mol Sci 2013; 14: 13391-13402. Go to original source... Go to PubMed...
    19. Elbl L, Hrstková H, Chaloupka V, et al. Poškození srdce protinádorovou léčbou. Praha: Grada, 2002: 156.
    20. Mladosievičová B, et al. Kardioonkologie: 2. přepracované a doplněné vydání. Praha: Grada, 2014: 208.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.